Fortress Biotech News

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first

GlobeNewswireMay 10 20:30

Checkpoint Therapeutics 1Q Loss $10.9M >CKPT

Checkpoint Therapeutics 1Q Loss $10.9M >CKPT

Dow JonesMay 10 20:30

Checkpoint Therapeutics 1Q Loss/Shr 33c >CKPT

Checkpoint Therapeutics 1Q Loss/Shr 33c >CKPT

Dow JonesMay 10 20:30

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024

SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of

GlobeNewswireMay 7 20:30

Mustang Bio Announces Closing of $4 Million Public Offering

WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell

GlobeNewswireMay 3 04:01

Journey Medical Corp: Appoints Joseph Benesch as Chief Fincl Officer

Journey Medical Corp: Appoints Joseph Benesch as Chief Fincl Officer

Dow JonesMay 2 04:03

Mustang Bio Announces Pricing of $4 Million Public Offering

WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell

GlobeNewswireApr 30 08:00

12 Health Care Stocks Moving In Wednesday's After-Market Session

GainersTrevena (NASDAQ:TRVN) shares increased by 27.0% to $0.51 during Wednesday's after-market session. The company's market cap stands at $9.2 million. Mustang Bio (NASDAQ:MBIO) stock increased by 1

BenzingaApr 18 04:31

Buy Rating Affirmed: A Promising Outlook for Fortress Biotech Amid Upcoming Regulatory Milestones and Strategic Investments

TipRanksApr 9 18:17

Fortress Biotech Q4 EPS $(0.53) Beats $(1.97) Estimate, Sales $19.95M Beat $14.89M Estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(1.97) by 73.1 percent. This is a 55.83 percent increase over losses of $(1.

BenzingaMar 29 11:33

Fortress Biotech GAAP EPS of -$8.47 Beats by $0.64, Revenue of $84.51M Beats by $4.83M

Seeking AlphaMar 29 04:57

Mustang Bio Stock Climbs 9% Amid Drug Development Update

Seeking AlphaMar 28 23:09

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion Into Autoimmune Diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024

GlobeNewswireMar 28 21:00

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the

GlobeNewswireMar 25 20:30

Press Release: Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasda

Dow JonesMar 22 20:30

Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target

Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target.

MT NewswiresMar 19 22:15

Fortress Biotech Initiated at Buy by Alliance Global Partners

Fortress Biotech Initiated at Buy by Alliance Global Partners

Dow JonesMar 19 20:30

Fortress Biotech Price Target Announced at $5.00/Share by Alliance Global Partners

Fortress Biotech Price Target Announced at $5.00/Share by Alliance Global Partners

Dow JonesMar 19 20:30

Alliance Global Partners Initiates Coverage On Fortress Biotech With Buy Rating, Announces Price Target of $5

Alliance Global Partners initiates coverage on Fortress Biotech (NASDAQ:FBIO) with a Buy rating and announces Price Target of $5.

BenzingaMar 19 20:20

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and

GlobeNewswireMar 18 20:30